Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Literature
1.
Altan B, Kaira K, Watanabe A, Kubo N, Bao P, Dolgormaa G, Bilguun EO, Araki K, Kanai Y, Yokobori T, Oyama T, Nishiyama M, Kuwano H, Shirabe K (2017) Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 81(1):141–153CrossRefPubMed
2.
Kleinbaum DG, Klein M (2006) Survival analysis: a self-learning text. Springer, New York
3.
Steyerberg E (2008) Clinical prediction models: a practical approach to development, validation, and updating. Springer, New York
4.
Weng J, Wu H, Xu Z, Xi H, Chen C, Chen D, Gong Y, Hua Y, Wang Z (2017) The role of propionic acid at diagnosis predicts mortality in patients with septic shock. J Crit Care 43:95–101CrossRefPubMed
5.
Metadata
Title
Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma
Authors
Jie Weng
Mengyun Tu
Bo Yang
Zhiyi Wang
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3551-6

Other articles of this Issue 2/2018

Cancer Chemotherapy and Pharmacology 2/2018 Go to the issue

Original Article

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Short Communication

Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report

Original Article

The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells

Original Article

The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer

Original Article

Pulmonary administration of curcumin inhibits B16F10 melanoma lung metastasis and invasion in mice

Original Article

Targeting ALK in pediatric RMS does not induce antitumor activity in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits